RxDoctor Payments Data

Louis Perdue, MD

Rheumatology · Metairie, LANPI 1184838716

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.7% of the total across 860 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 21.3% — the pattern of someone who eats at a lot of different presentations.

$16,919in general payments, 2019–2025

Across 860 payments — averaging $19.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$4K
  • Pfizer$1K
  • Johnson & Johnson$1K
  • UCB, Inc.$950
  • Novartis$782
  • plus $6K from 35 others

What the payments were for

  • Speaking & faculty fees$1,2507%
  • Food & beverage$15,51792%
  • Education$1521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,919 in reported general payments places this provider in the 75th percentile of 88 rheumatology providers in Louisiana.

See all rheumatology providers in Louisiana

Medicare billing

Part B allowed, 2024
$1,203,851
Medicare patients
478
Services billed
85,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib60$454,221
Humira(Cf) PenAdalimumab38$309,827
Enbrel SureclickEtanercept23$241,361
EnbrelEtanercept21$128,746
ProliaDenosumab63$110,003
Enbrel MiniEtanercept12$90,753
Xeljanz XrTofacitinib Citrate14$79,656
Taltz AutoinjectorIxekizumab11$71,703
BenlystaBelimumab12$56,948
ActemraTocilizumab13$34,734
Mycophenolate Mofetil96$28,148
Hydroxychloroquine Sulfate595$16,438
Colchicine418$14,351
Tramadol Hcl921$9,973
Celecoxib312$8,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$3,584$454,22160 claims
AmgenEnbrel, Prolia$3,609$238,74984 claims
GSKBenlysta$410$56,94812 claims
Hikma Pharmaceuticals USAMitigare$247$5,04015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 88 rheumatology providers in Louisiana.

Other rheumatology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →